文献速递免疫规划

20价肺炎球菌结合疫苗与四价流感疫苗联合接种的安全性和免疫原性:一项3期随机试验

Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
PubMed 文献 · Vaccine · 2023-02-23

这项3期随机双盲多中心研究纳入1796名美国≥65岁成人,1:1随机接受PCV20与QIV联合接种(联合接种组)或QIV后1个月接种PCV20(分开接种组)。结果显示,联合接种组对全部20种肺炎球菌血清型和全部4种流感疫苗株的抗体应答非劣效于分开接种组;局部反应和全身事件多为轻中度,联合接种组轻度和中度疲劳报告率高于分开接种组,但被认为无临床意义;不良事件报告率组间相似,无严重不良事件被认为与接种相关。

要点

  • PCV20与QIV联合接种对全部20种肺炎球菌血清型和全部4种流感疫苗株的抗体应答非劣效于分开接种。
  • 联合接种组轻度和中度疲劳报告率高于分开接种组(轻度20.0% vs 10.8%-12.6%;中度12.3% vs 8.4%-9.6%),被认为无临床意义。
  • 不良事件报告率组间相似,无严重不良事件被认为与接种相关。

核心结论

  • PCV20与QIV联合接种后的免疫应答非劣效于任一疫苗分开接种;PCV20与QIV同时或之后接种的安全性特征相似;这些发现支持PCV20与QIV联合接种。

研究设计与样本

  • 3期随机双盲多中心研究,纳入1796名美国≥65岁成人,1:1随机分为联合接种组(PCV20与QIV,1个月后生理盐水)和分开接种组(QIV与生理盐水,1个月后PCV20)。

主要发现

  • 联合接种组对比分开接种组,全部20种肺炎球菌血清型的OPA几何均值比95%CI下限>0.5、全部4种流感疫苗株的HAI几何均值比95%CI下限>0.67,达到非劣效。
  • 局部反应和全身事件在各组多为轻中度;注射部位疼痛是最常见局部反应,疲劳是最常见全身事件。
  • 联合接种组轻度和中度疲劳报告率高于分开接种组(轻度20.0% vs 10.8%-12.6%;中度12.3% vs 8.4%-9.6%),被认为无临床意义。
  • 不良事件报告率组间相似,无严重不良事件被认为与接种相关。

关键数值与推荐

  • 非劣效标准:PCV20的OPA几何均值比95%CI下限>0.5,QIV的HAI几何均值比95%CI下限>0.67。

临床怎么用

  • 原文结论指出这些发现支持PCV20与QIV联合接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Older adults are at increased risk of adverse outcomes from pneumococcal disease and influenza infections. Vaccination is an established strategy for preventing both illnesses. This study evaluated coadministration of 20-valent pneumococcal conjugate vaccine (PCV20) and an adjuvanted quadrivalent inactivated influenza vaccine (QIV). METHODS: This phase 3, randomized, double-blind, multicenter study included 1796 US adults ≥ 65 years of age randomized 1:1 to receive either PCV20 and QIV followed 1 month later by saline (Coadministration group) or QIV and saline followed 1 month later by PCV20 (Separate Administration group). Primary immunogenicity objectives were to show noninferiority of PCV20 and QIV coadministration compared with separate administration of either vaccine based on serotype-specific opsonophagocytic activity (OPA) titers for PCV20 and strain-specific hemagglutination inhibition assay (HAI) titers for QIV. Safety endpoints included local reactions, systemic events, and adverse events (AEs). RESULTS: Noninferiority for pneumococcal and influenza antibody responses (lower bound 95 % CI of the OPA and HAI geometric mean ratios of > 0.5 and > 0.67, respectively) was shown for the Coadministration group compared with the Separate Administration group for all 20 pneumococcal serotypes and all 4 influenza vaccine strains. Local reactions and systemic events were mostly mild or moderate in severity across groups; injection site pain was the most frequent local reaction, and fatigue was the most frequent systemic event. Mild and moderate fatigue were reported more frequently after PCV20 and QIV coadministration compared with separate administration (mild, 20.0 % vs 10.8 %-12.6 %; moderate, 12.3 % vs 8.4 %-9.6 %); this was not considered clinically significant. AE reporting rates were similar across groups, and no serious AEs were considered vaccination-related. CONCLUSIONS: Immune responses after coadministration of PCV20 and QIV were noninferior to separate administration of either vaccine. The PCV20 safety profile was similar when given together with or after QIV. These findings support PCV20 and QIV coadministration. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04526574.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cannon K, Cardona JF, Yacisin K, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial. Vaccine. 2023. PMID: 36828719. doi:10.1016/j.vaccine.2022.11.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。